• The goal of this clinical research study is to learn about the safety and tolerability of paclitaxel and carboplatin when given in combination with Avastin to patients with ovarian, primary peritoneal, or fallopian tube cancer. [ Time Frame: 4 Years ] [ Designated as safety issue: Yes ]
  

Inclusion Criteria:

1. Histologically confirmed epithelial carcinoma of mullerian origin. Specifically, ovarian, primary peritoneal and tubal carcinoma will be allowed. All histologic subtypes are eligible.
2. Stage III or IV disease. Stage IV disease by virtue of pleural effusions is allowed but stage IV disease with visceral metastases e.g. lung, liver or abdominal wall is NOT ELIGIBLE. Please discuss any eligibility concerns directly with the P.I., Dr. Carolyn Krasner.
3. Patient must have undergone surgical staging and debulking with optimal (less than 1cm) cytoreduction.
4. No significant intra-abdominal adhesions or other contraindication to IP port placement.
5. Patients must give written informed consent.
6. Patient must be age 18 years or older.
7. Adequate bone marrow function with an ANC greater that 2,500 and Platelets greater than 100,000 cubic millimeters.
8. No proteinuria or less than +1; if greater, 24-hour urine collection must be performed to document less than or equal to 1gm/24 hours of protein.
9. ECOG performance status less than or equal to 1.

Exclusion Criteria:

1. ECOG performance status greater than or equal to 2
2. Previous chemotherapy
3. Suboptimal (greater than 1 cm residual disease) cytoreduction
4. Creatinine greater than 1.5 mg/dL
5. SGOT greater than 2 x ULN, bilirubin greater than 1.5 x ULN
6. Colostomy or ileostomy
7. Concurrent invasive malignancy. (Patients with concurrent superficial endometrial carcinoma are eligible if their endometrial carcinoma is superficial or invades less than 50% the thickness of the myometrium.)
8. Known hypersensitivity to E.coli derived products or to any component of Avastin
9. Active psychiatric or mental illness that makes informed consent or careful clinical follow-up unlikely
10. History of myocardial infarction within 6 months
11. History of stroke or transient ischemia attack within 6 months
12. Inadequately controlled hypertension greater than 140/90 mm Hg on antihypertensive medication(s)
13. Any prior history of hypertensive crisis or hypertensive encephalopathy
14. Clinically significant peripheral vascular disease
15. Significant vascular disease (e.g. aortic aneurysm, aortic dissection)
16. Unstable angina
17. New York Heart Association (NYHA) grade II or greater congestive heart failure
18. Evidence of coagulopathy or bleeding diathesis
19. Known central nervous system disease or brain metastases
20. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 28 (first dose of Avastin), anticipation of need for major surgical procedure during the course of the study
21. Minor surgical procedures such as fine needle aspirations or core biopsies or laparoscopy for IP catheter placement within 7 days prior to cycle 2 day 8
22. Open wound, ulcer, or bone fracture
23. History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess; current signs and symptoms of bowel obstruction; current dependency on IV hydration or TPN
24. Pregnant (positive pregnancy test) or lactating